GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PaxMedica Inc (OTCPK:PXMD) » Definitions » Days Sales Outstanding

PXMD (PaxMedica) Days Sales Outstanding : 0.00 (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is PaxMedica Days Sales Outstanding?

PaxMedica's average Accounts Receivable for the three months ended in Jun. 2024 was $0.00 Mil. PaxMedica's Revenue for the three months ended in Jun. 2024 was $0.00 Mil.

The historical rank and industry rank for PaxMedica's Days Sales Outstanding or its related term are showing as below:

PXMD's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 72.59
* Ranked among companies with meaningful Days Sales Outstanding only.

PaxMedica's Days Sales Outstanding stayed the same from Jun. 2023 (0.00) to Jun. 2024 (0.00).


PaxMedica Days Sales Outstanding Historical Data

The historical data trend for PaxMedica's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PaxMedica Days Sales Outstanding Chart

PaxMedica Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Sales Outstanding
Get a 7-Day Free Trial - - - - -

PaxMedica Quarterly Data
Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PaxMedica's Days Sales Outstanding

For the Biotechnology subindustry, PaxMedica's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PaxMedica's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PaxMedica's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where PaxMedica's Days Sales Outstanding falls into.



PaxMedica Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

PaxMedica's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

Days Sales Outstanding (A: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2022 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (0 + 0) / 1 ) / 0*365
=0 / 0*365
=N/A

PaxMedica's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:

Days Sales Outstanding (Q: Jun. 2024 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Mar. 2024 ) + Accounts Receivable (A: Jun. 2024 )) / count ) / Revenue (A: Jun. 2024 )*Days in Period
=( (0 + 0) / 1 ) / 0*365 / 4
=0 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PaxMedica  (OTCPK:PXMD) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


PaxMedica Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of PaxMedica's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


PaxMedica Business Description

Traded in Other Exchanges
N/A
Address
303 South Broadway, Suite 125, Tarrytown, NJ, USA, 10591
PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.
Executives
Zachary Rome director, officer: Chief Operating Officer C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Howard J. Weisman director, officer: Chief Executive Officer C/O PAXMEDICA, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Karen Larochelle director 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
John F Coelho director 22 BENEDICT CRESCENT, BASKING RIDGE NJ 07920
Michael Derby director, officer: Executive Chairman 303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027
David W. Hough officer: Chief Medical Officer C/O PAXMEDICA, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Tardimed Sciences Llc 10 percent owner 303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
Stephen Sheldon officer: Chief Financial Officer 2 REVOLUTIONARY WAY, #312, HOPKINTON MA 01748